Rigel Pharmaceuticals, Incorporated

Eli Lilly and Company

Esteban Masuda

Rajinder Paul Singh

Somasekhar Bhamidipati

Vanessa Taylor

Sacha Holland

Rao Kolluri

Kin Tso

Thomas Weitao Sun

Hui Li

Donald G Payan

Todd M Kinsella

David C Anderson

Mark K Bennett

Justin E Warner

Taisei Kinoshita

Simon Shaw

Matthew Duncton

Salvador Alvarez

Ankush Argade

Yan Chen

Ihab S Darwish

Jiaxin Yu

Thilo J Heckrodt

Pingyu Ding

Jing Zhang

Valentino J Stella

Rose Yen

Brian Wong

Jeffrey Clough

David Carroll

Sambaiah Thota

Arvinder Sran

Ryan Kelley

Dane A Goff

Mark Powell

Haoran Zhao

Marcy K Vallone

Darren J McMurtrie

Robin Cooper

X Charlene Liao

Tarikere Gururaja

Stephanie Yung

Mark Irving

Peter Chu

Rongxian Ding

Elliot B Grossbard

Yasumichi Hitoshi

Jack Maung

Vadim Markovtsov

James B Lorens

Zhushou Luo

Valeria S Ossovskaya

Ying-Ping Jiang

Annabelle Friera

Polly Pine

Robert Booher

Jorge Pardo

Congfen Li

Denise Pearsall

Jochen Schmitz

Collin Spencer

Annabelle Freiro

Chrystelle Lamagna

David Sweeny

Dane Goff

Jeffrey Wayne Clough

Elliott B Grossbard

Darren Mcmurtrie

Disclosed embodiments concern compounds according to Formula I In some embodiments, the compounds are useful as kinase inhibitors, such as interleukin receptor associated kinases (IRAK) inhibitors. Also disclosed are compositions comprising such inhibitors, and methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent a kinase-associated disease or condition, particularly an IRAK-associated disease or condition.

Tricyclic IRAK inhibitors

Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitor compounds and compositions comprising such compounds. The compounds may have a structure according to Formula I Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

Pyrimid-2-yl-pyrazole compounds as IRAK inhibitors

Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

RIP1K inhibitors

Provided herein are a variety of methods that involve administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having or suspected of having a COVID-19 infection. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop acute respiratory distress syndrome, acute kidney injury, and/or thrombosis. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop symptoms associated with a cytokine response. Aspects of the methods may further include identifying a patient with kidney malfunction, e.g., acute kidney injury, and/or thrombosis.

Method for treatment of COVID-19-associated conditions

RIP1 inhibitory compounds and methods for making and using the same

Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to inhibit a RIP1 kinase in vivo or ex vivo, and also may treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.

Tyrosine kinase inhibitors

The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.

Compositions and methods for inhibition of the JAK pathway

The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.

Prodrugs of 2,4-pyrimidinediamine compounds and their uses

Growing community of inventors

Menlo Park, CA, United States of America

Esteban Masuda